Docetaxel, carboplatin, trastuzumab and pertuzumab with or without estrogen deprivation in treating patients with hormone receptor-positive, HER2-positive operable or locally advanced breast cancer.
Clinical Trial Categories
National Cancer Institute (NCI)
Research study staff: 425.688.5407
Overlake Medical Center
1035 116th Ave. NE
Bellevue, WA 98004